Fu Z, Sun H, Wu Y, Li C, Wang Y, Liu Y
A study published in JAMA in January 2025 which looked at more than 125,000 overweight or obese people found that nearly 47% of those with type 2 diabetes and 65% of those without diabetes stopped taking their prescribed GLP-1s within a year of starting them
Retatrutide is the appropriate compound for studies that require investigation of all three incretin-adjacent pathways simultaneously, for energy expenditure research that goes beyond appetite suppression, and for comparative studies against semaglutide and tirzepatide in metabolic models
But a lot of individuals also report this sort of rebound like ravenous hunger that happens off of it almost as if the body is sort of resetting to the native or what our body normally makes in terms of GLP
Multiple studies revealed the processes underlying this axis and led to the development of effective microbiota-based drugs for both prevention and treatment
For many people, using semaglutide weekly marks the end of cravings, frenzied eating, and constant feelings of hunger